专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

US08597614B2 Diagnosis and treatment of mood disorders 有权
标题翻译：情绪障碍的诊断和治疗
公开(公告)号：US08597614B2
公开(公告)日：2013-12-03
申请号：US11997406
申请日：2006-08-02
申请人： Jeffrey Hugh Meyer , Nathalie Ginovart
发明人： Jeffrey Hugh Meyer , Nathalie Ginovart
IPC分类号： A61K51/00 , A61M36/14
CPC分类号： G01N33/573 , G01N33/60 , G01N2333/902 , G01N2500/00 , G01N2800/304
摘要： The present invention relates to the diagnosis, treatment and monitoring of mood disorders. For example, a diagnosis may be performed by determining whether a monoamine oxidase in a vertebrate is elevated compared to a healthy control subject. Methods of monitoring treatments and methods for identifying treatments for mood disorders are also provided.
摘要翻译：本发明涉及情绪障碍的诊断，治疗和监测。例如，可以通过确定与健康对照受试者相比，脊椎动物中单胺氧化酶是否升高来进行诊断。还提供了监测治疗方法和用于鉴别情绪障碍治疗的方法。

52. 发明申请

US20130202600A1 Polypeptides And Methods For Modulating D1-D2 Dopamine Receptor Interaction And Function 审中-公开
标题翻译：多肽和调节D1-D2多巴胺受体相互作用和功能的方法
公开(公告)号：US20130202600A1
公开(公告)日：2013-08-08
申请号：US13862010
申请日：2013-04-12
申请人： Centre for Addiction and Mental Health
发明人： FANG LIU
IPC分类号： C07K16/28 , C07K14/47
CPC分类号： C07K14/70571 , A61K38/00 , C07K14/47 , C07K16/286 , C07K2319/10
摘要： The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.
摘要翻译：本发明提供预防和/或治疗涉及D1-D2多巴胺受体偶联和/或活化异常的神经或神经精神障碍。提供了用于调节由D1-D2偶联和/或激活产生的多巴胺受体功能的方法和试剂。本发明的药剂包括可以破坏D1-D2偶联的D2受体或D1受体的片段。

53. 发明申请

US20110097324A1 COMPOSITIONS AND METHODS FOR MODULATING NICOTINIC/NMDA RECEPTOR FUNCTION 审中-公开
标题翻译：用于调节NICOTINIC / NMDA受体功能的组合物和方法
公开(公告)号：US20110097324A1
公开(公告)日：2011-04-28
申请号：US12997820
申请日：2009-06-15
申请人： Fang Liu
发明人： Fang Liu
IPC分类号： A61K39/395 , A61P25/30 , A61K31/7088 , A61K38/14 , C07K7/06 , C07K7/08 , C07K14/00 , C07H21/04 , C12N5/02
CPC分类号： C07K14/70571 , A61K38/00 , C07K2319/10
摘要： The present invention provides a method for modulating nicotinic/NMDA receptor function in a mammal in need of such treatment comprising administering a therapeutically effective amount of an agent that disrupts heterodimerization of α7 neuronal nicotinic acetylcholine receptors and N-methyl-D-asparate glutamate receptor. A polypeptide and fragments thereof comprising an amino acid sequence selected from the second intracellular loop of the α7 nAchR and carboxyl tail of the N-methyl-D-aspartate receptor are also provided, which are able to inhibit the heterodimerization. Also disclosed are nucleotide sequences encoding the polypeptides, and methods of inhibiting the heterodimerization of α7 nAchR and NMDAR using the polypeptides and nucleic acids.
摘要翻译：本发明提供了一种在需要这种治疗的哺乳动物中调节烟碱/ NMDA受体功能的方法，包括给予治疗有效量的破坏α7神经元烟碱乙酰胆碱受体和N-甲基-D-天冬氨酸谷氨酸受体的异源二聚化的试剂。还提供了能够抑制异源二聚化的包含选自α7nArR的第二细胞内环和N-甲基-D-天冬氨酸受体的羧基末端的氨基酸序列的多肽及其片段。还公开了编码多肽的核苷酸序列，以及使用多肽和核酸抑制α7nAchR和NMDAR的异源二聚化的方法。

54. 发明授权

US07794934B2 Predicting negative symptom change during drug treatment 有权
标题翻译：预测药物治疗期间的阴性症状变化
公开(公告)号：US07794934B2
公开(公告)日：2010-09-14
申请号：US11394187
申请日：2006-03-31
申请人： Livia Martucci , James Kennedy
发明人： Livia Martucci , James Kennedy
IPC分类号： C12Q1/68 , C07H21/04 , C12P19/34
CPC分类号： C12Q1/6883 , A61K31/5513 , C12Q1/6876 , C12Q2600/106 , C12Q2600/156
摘要： A method for predicting a negative symptom change in a subject during drug therapy is provided. The method comprises isolating genomic DNA from a sample of the subject, and genotyping a T5988C marker of GRIN2B gene. A GRIN2B 5988 T/T genotype is predictive of a negative symptom improvement in the subject in response to drug therapy. The drug therapy may be clozapine therapy. Also provided is a method of identifying a polymorphism in a nucleotide sequence of interest that is predictive of response to drug therapy comprising the steps of assessing negative symptom improvement in a plurality of subjects during the course of drug therapy, isolating a sample comprising DNA from each subject, genotyping one or more nucleotide sequences of interest in the DNA of each subject to identify one or more polymorphisms that exist in the one or more nucleotide sequences of interest, wherein correlation of a significant improvement of negative symptoms with one or more polymorphisms is predictive of response to drug therapy.
摘要翻译：提供了一种在药物治疗期间预测受试者的阴性症状变化的方法。该方法包括从受试者的样品中分离基因组DNA，并对GRIN2B基因的T5988C标记进行基因分型。 GRIN2B 5988 T / T基因型可预测受试者对药物治疗的负面症状改善。药物治疗可能是氯氮平治疗。还提供了鉴定预期对药物治疗的反应的感兴趣的核苷酸序列中的多态性的方法，包括以下步骤：在药物治疗过程中评估多个受试者的阴性症状改善，从每个样品中分离包含DNA的样品受试者，对每个受试者的DNA中的一个或多个感兴趣的核苷酸序列进行基因分型，以鉴定存在于一个或多个感兴趣的核苷酸序列中的一个或多个多态性，其中阴性症状与一种或多种多态性的显着改善的相关性是预测性的对药物治疗的反应。

55. 发明授权

US07666597B2 Marker for tardive dyskinesia 失效
标题翻译：标记迟发性运动障碍
公开(公告)号：US07666597B2
公开(公告)日：2010-02-23
申请号：US11538073
申请日：2006-10-03
申请人： James Lowery Kennedy , Clement C. Zai
发明人： James Lowery Kennedy , Clement C. Zai
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/70 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention discloses markers for tardive dyskinesia. Also disclosed is a method of determining the risk of tardive dyskinesia from antipsychotic medication in a subject, the method comprising the step of genotyping a sample obtained from the subject for the rs905568 polymorphism, wherein a subject comprising a CC, CG or GC genotype is at increased risk for tardive dyskinesia as compared to a subject comprising the GG genotype. Kits for practicing the method are also disclosed.
摘要翻译：本发明公开了用于迟发性运动障碍的标记物。还公开了一种确定受试者中抗精神病药物的迟发性运动障碍的风险的方法，该方法包括将从受试者获得的样品基因分型为rs905568多态性的步骤，其中包含CC，CG或GC基因型的受试者处于与包含GG基因型的受试者相比，延迟性运动障碍的风险增加。还披露了用于实施该方法的套件。

56. 发明授权

US07368264B2 SLC1A1 marker for anxiety disorder 有权
标题翻译： SLC1A1焦虑症标志物
公开(公告)号：US07368264B2
公开(公告)日：2008-05-06
申请号：US11591244
申请日：2006-10-31
申请人： Paul Daniel Arnold , Margaret A. Richter , James Lowery Kennedy
发明人： Paul Daniel Arnold , Margaret A. Richter , James Lowery Kennedy
IPC分类号： C12P19/34
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention provides methods for diagnosing or identifying susceptibility of a subject to an anxiety or mood disorder. One method involves testing a sample obtained from the subject for the presence of a polymorphism in Intron 10 of the SLC1A1 gene. The presence of allele G or allele A of the A/G polymorphism rs301434 indicates that the patient is susceptible to an anxiety disorder. An alternate method involves testing a sample obtained from the subject for the presence of a polymorphism in the 3′ untranslated region of the SLC1A1 gene. The presence of allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to an anxiety disorder. Furthermore, a method is provided that involves testing a sample obtained from the subject for the presence of a haplotype in the SLC1A1 gene, wherein the combined presence allele G of the A/G polymorphism rs301434 and allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to a mood disorder.
摘要翻译：本发明提供用于诊断或鉴定受试者对焦虑或情绪障碍的易感性的方法。一种方法包括测试从受试者获得的样品在SLC1A1基因的内含子10中存在多态性。 A / G多态性rs301434等位基因G或等位基因A的存在表明患者易患焦虑症。一种替代方法包括测试从受试者获得的样品在SLC1A1基因的3'非翻译区中存在多态性。 C / G多态性rs3087879等位基因C的存在表明患者易患焦虑症。此外，提供了一种方法，其包括测试从受试者获得的样品中SLC1A1基因中单体型的存在，其中A / G多态性rs301434的组合存在等位基因G和C / G多态性rs3087879的等位基因C表明患者容易发生心境障碍。

57. 发明申请

US20070231801A1 Predicting negative symptom change during drug treatment 有权
标题翻译：预测药物治疗期间的阴性症状变化
公开(公告)号：US20070231801A1
公开(公告)日：2007-10-04
申请号：US11394187
申请日：2006-03-31
申请人： Livia Martucci , James Kennedy
发明人： Livia Martucci , James Kennedy
IPC分类号： C12Q1/68 , C12P19/34
CPC分类号： C12Q1/6883 , A61K31/5513 , C12Q1/6876 , C12Q2600/106 , C12Q2600/156
摘要： A method for predicting a negative symptom change in a subject during drug therapy is provided. The method comprises isolating genomic DNA from a sample of the subject, and genotyping a T5988C marker of GRIN2B gene. A GRIN2B 5988 T/T genotype is predictive of a negative symptom improvement in the subject in response to drug therapy. The drug therapy may be clozapine therapy. Also provided is a method of identifying a polymorphism in a nucleotide sequence of interest that is predictive of response to drug therapy comprising the steps of assessing negative symptom improvement in a plurality of subjects during the course of drug therapy, isolating a sample comprising DNA from each subject, genotyping one or more nucleotide sequences of interest in the DNA of each subject to identify one or more polymorphisms that exist in the one or more nucleotide sequences of interest, wherein correlation of a significant improvement of negative symptoms with one or more polymorphisms is predictive of response to drug therapy.
摘要翻译：提供了一种在药物治疗期间预测受试者的阴性症状变化的方法。该方法包括从受试者的样品中分离基因组DNA，并对GRIN2B基因的T5988C标记进行基因分型。 GRIN2B 5988 T / T基因型可预测受试者对药物治疗的负面症状改善。药物治疗可能是氯氮平治疗。还提供了鉴定预期对药物治疗的反应的感兴趣的核苷酸序列中的多态性的方法，包括以下步骤：在药物治疗过程中评估多个受试者的阴性症状改善，从每个样品中分离包含DNA的样品受试者，对每个受试者的DNA中的一个或多个感兴趣的核苷酸序列进行基因分型，以鉴定存在于一个或多个感兴趣的核苷酸序列中的一个或多个多态性，其中阴性症状与一种或多种多态性的显着改善的相关性是预测性的对药物治疗的反应。

58. 发明公开

US20240374612A1 IMIDAZOBENZODIAZEPINES FOR TREATMENT OF COGNITIVE AND MOOD SYMPTOMS 审中-公开
公开(公告)号：US20240374612A1
公开(公告)日：2024-11-14
申请号：US18690342
申请日：2022-09-08
申请人： UWM Research Foundation, Inc. , Centre for Addiction and Mental Health
发明人： Thomas Damien Prevot , Michael Jeffrey Marcotte , Etienne Laurent Sibille , James M. Cook , Guangan Li , Prithu Mondal , Md Yeunus Mian , Farjana Rashid
IPC分类号： A61K31/5517 , A61P25/00 , C07D487/04
CPC分类号： A61K31/5517 , A61P25/00 , C07D487/04
摘要： 4H-Benzo[f]imidazo [1,5-a][1,4]diazepines substituted in the 3-position with an amide or oxadiazole and their pharmaceutical compositions display efficacy to enhance cognition and may have utility in the treatment of cognitive deficiencies, such as in neurodegenerative and neuropsychiatric disorders.

59. 发明授权

US11763929B2 Medical tool aiding diagnosed psychosis patients in detecting auditory psychosis symptoms associated with psychosis 有权
公开(公告)号：US11763929B2
公开(公告)日：2023-09-19
申请号：US17819603
申请日：2022-08-12
申请人： Centre for Addiction and Mental Health , Memotext Corporation
发明人： Sean Andrew Kidd , Amos Adler , Hesamaldin Nekouei , Linda Kaleis
IPC分类号： G16H20/70 , A61B5/00 , A61B5/16 , A61M21/00
CPC分类号： G16H20/70 , A61B5/0022 , A61B5/165 , A61B5/746 , A61M21/00 , A61B5/4803 , A61B2562/0204 , A61M2021/0027 , A61M2205/18 , A61M2205/3375 , A61M2205/50
摘要： A medical tool is described for supporting an individual suffering from a mental condition or disorder characterized by auditory psychosis symptoms. The tool can assist in training the individual to distinguish between an acute auditory psychosis episode and ambient sounds. The tool can monitor for a non-audio input by a patient, where the input represents an indication that the patient is hearing sounds potentially symptomatic of psychosis. A microphone can monitor ambient sounds, which are tested against a threshold to determine and whether an auditory psychosis episode may be occurring.

60. 发明申请

US20220105106A1 COMPOSITIONS AND METHODS RELATING TO USE OF AGONISTS OF ALPHA5-CONTAINING GABAA RECEPTORS 有权
公开(公告)号：US20220105106A1
公开(公告)日：2022-04-07
申请号：US17310549
申请日：2020-02-12
申请人： Centre for Addiction and Mental Health
发明人： Thomas D. Prevot , Mounira Banasr , Etienne Sibille
IPC分类号： A61K31/5517 , A61P25/28
摘要： The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式